Peptide YY Analogue (Cagrilintide Component)
Native GLP-1 (7-37) is the endogenous 31-aa incretin secreted by intestinal L-cells. It potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. The structural template for semaglutide, liraglutide, and exenatide.
Community Rating
No ratings yet
⚠ Research & Educational Use Only. Peptide YY Analogue (Cagrilintide Component) is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Potentiates glucose-dependent insulin secretion from beta cells — the defining incretin mechanism
- Suppresses postprandial glucagon secretion from alpha cells — reduces hepatic glucose output
- Slows gastric emptying — modulates rate of nutrient absorption after meals
- Peptide YY Analogue (Cagrilintide Component) is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Potentiates glucose-dependent insulin secretion from beta cells — the defining incretin mechanism
- Suppresses postprandial glucagon secretion from alpha cells — reduces hepatic glucose output
- Slows gastric emptying — modulates rate of nutrient absorption after meals
- Reduces appetite via GLP-1R on hypothalamic neurons (arcuate nucleus) and area postrema
What is Peptide YY Analogue (Cagrilintide Component)?
Tap any underlined term for an instant definition.
Native GLP-1 (Glucagon-Like Peptide-1, 7-37) is a 31-amino acid incretin hormone produced by post-translational processing of proglucagon in intestinal L-cells, enteric neurons, and the nucleus of the solitary tract in the brainstem. The biologically active forms are GLP-1(7-37) and GLP-1(7-36)amide; the latter is the predominant circulating form.
GLP-1 is secreted within 10-15 minutes of a meal in proportion to meal caloric content, with the fastest rise occurring in response to combined fat and carbohydrate intake. Its secretion is mediated by both direct L-cell stimulation (distal gut contact with nutrients) and neural (vagal) reflexes from proximal nutrient sensing.
**Mechanism of action via GLP-1R:** 1. **Pancreatic beta cells**: cAMP-mediated potentiation of KATP channel closure → depolarization → insulin secretion (glucose-dependent) 2. **Pancreatic alpha cells**: suppresses glucagon secretion (indirect, via somatostatin and direct alpha-cell GLP-1R) 3. **Stomach**: vagal GLP-1R activation slows gastric emptying 4. **Hypothalamus/brainstem**: GLP-1R in arcuate nucleus, paraventricular nucleus, and area postrema → satiety, nausea 5. **Heart**: GLP-1R on cardiomyocytes → cardioprotection (MACE reduction in cardiovascular outcome trials)
The critical limitation of native GLP-1 is its ~1-2 minute plasma half-life due to N-terminal DPP-IV cleavage at position 2 (His-Ala motif). This limitation drove the development of the entire GLP-1R agonist drug class — by modifying the His-Ala motif, extending the peptide, or attaching fatty acid chains for albumin binding, pharmaceutical companies produced once-daily and once-weekly injectable drugs (liraglutide, semaglutide, dulaglutide, exenatide ER) and even oral formulations (oral semaglutide).
GLP-1's research applications span metabolic disease, cardiovascular disease (LEADER, SUSTAIN-6, AMPLITUDE-O trials demonstrated cardiovascular protection), neurodegenerative disease (GLP-1R on dopaminergic neurons; liraglutide studied in Parkinson's disease), and non-alcoholic steatohepatitis (NASH).
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Peptide YY Analogue (Cagrilintide Component). See all Metabolic & Weight peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Native GLP-1 is used as a research reference standard in incretin studies. Clinical applications use long-acting analogues:
Research IV infusion: 0.75-1.5 pmol/kg/min continuous IV infusion for acute metabolic studies Exenatide (twice-daily): 5-10 mcg SC BID (reference GLP-1R agonist) Liraglutide: 0.6-1.8 mg SC daily Semaglutide (weekly): 0.5-2 mg SC weekly or 3-14 mg oral daily
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Native GLP-1 is exclusively used as a research tool in acute infusion studies. All clinical and translational research uses DPP-IV-resistant long-acting analogues.
Explore Further
Quick Reference
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.